24 April, 2014 02:12 IST
News
India Ratings affirms Aurobindo Pharma at `AA-`
Source: IRIS (16-NOV-12)
Comments  |  Post Comment

India Ratings has affirmed Aurobindo Pharma (APL) Long-Term Issuer rating at ‘AA-'. The outlook is stable. The affirmation reflects India Ratings’ opinion that APL’s revenue visibility over the medium term remains strong driven by new product launches, mainly in the US. This, along with better fixed cost absorption from higher plant capacity use, is likely to lead to an improvement in EBITDA margins from FY13 (year ending March). As a result, financial leverage (adjusted debt net of cash/EBITDA) is likely to see a sustained improvement over the medium term.

Financial leverage deteriorated to 5.0x in FY12 from 2.3x in FY11 due to an increase in debt to Rs 30 billion from Rs 24 billion and a decline in EBITDA margin to 12.4% from 24.9%. The increase in debt was partly due to restatement of foreign currency debt (Rs 3.5 billion). Also, the company reported muted revenue growth of 10.5% yoy in FY12. This is because during FY11 USFDA had sanctioned APL’s Unit 3 and Unit 6 which negatively impacted APL’s export sales to the US during FY12 and also affected the off-take by Pfizer for the US market. The decline in margins is attributed to lower dossier income, one-time incremental expenses and lower absorption of fixed costs on the affected plants.

The increase in APL's revenue and profitability coupled with limited capex is likely to translate into positive free cash flows and a decline in total adjusted debt over the medium-to-long term. Minimal scheduled debt repayments, along with stable working capital, are likely to keep liquidity comfortable over the short term. 

APL expects USFDA to lift all sanctions and also to approve its new Unit 4 during H2FY12. Commencement of exports from Unit 6 and Unit 4 will support revenue growth. To manage revenue growth, APL has set up a distribution network in the US through which it sells majority of its generic formulations. As on end-June 2012, APL’s product portfolio consisted of 152 USFDA approved finished dosage forms (FDFs) and another close to 200 products approved in Europe and South Africa and a long pipeline of products in multiple therapeutic segments.

Shares of the company gained Rs 3.5, or 2.02%, to trade at Rs 177.10. The total volume of shares traded was 514,364 at the BSE (3.54 p.m., Friday).



Aurobindo Pharma Limited   (Q,N,C,F)*


News
UltraTech Cement standalone quarterly net climbs 15.40% - 23-Apr-2014 18:38
Indiabulls Wholesale Services standalone quarterly net falls 35.05% - 23-Apr-2014 18:36
Kirloskar Pneumatic Company standalone quarterly earnings rise 18.78% - 23-Apr-2014 18:32
Indbank Merchant Banking Services swings to profit in Jan-Mar quarter - 23-Apr-2014 18:23
Sabero Organics Gujarat standalone quarterly net declines 27.22% - 23-Apr-2014 17:32
Shree Digvijay Cement Company standalone quarterly profit zooms 2.31 times - 23-Apr-2014 17:24
Cairn India consolidated Q4 profit climbs 18.4% - 23-Apr-2014 17:13
Infosys in strategic alliance with Orange - 23-Apr-2014 16:44
B S L standalone quarterly net surges 60.00% - 23-Apr-2014 16:11
Mastek standalone quarterly earnings plunges 77.61% - 23-Apr-2014 16:09
Mahindra's agri division enters into JV with HZPC, Holland - 23-Apr-2014 15:52
more...
* Q - Quote , N - News , C - Chart , F - Financials
Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type   hhs3dz into this box
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Forums  |   E-mail  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer